DEERFIELD, Ill., May 19, 2011 /PRNewswire/ — Astellas Pharma
US, Inc. (“Astellas”) recently hired Mark Reisenauer as vice
president of sales and marketing, oncology. Reporting directly to
Patrick Shea, senior vice president of marketing & sales,
Reisenauer will be responsible for all U.S. commercial activities
supporting marketed products, the company’s oncology co-promotion
partners and will lead commercial planning for early stage
development compounds.
“Astellas has made significant progress over the last year
toward becoming a global category leader in oncology with the
integration of OSI oncology and further development of the
pipeline. Mark’s breadth of product experience, along with his
proven leadership capabilities, will be instrumental in Astellas’
future success in oncology,” said Shea. “We are excited to add Mark
to our management team.”
The majority of Mark’s 20-plus year career has been committed to
oncology therapies, where he has had sales and marketing
responsibilities in a variety of capacities (domestic and global)
at Abbott, Pharmacia, Bristol-Myers Squibb and Zeneca. Most
recently, Mark has served as senior vice president and chief
commercial officer of Micromet Inc. where he was involved in
investor and public relations, clinical strategy, business
development, and commercial launch planning.
About Astellas
Astellas Pharma US, Inc., located in Deerfield, Illinois, is a
U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a
pharmaceutical company dedicated to improving the health of people
around the world through the provision of innovative and reliable
pharmaceutical products. The organization is committed to becoming
a global category leader in focused areas by combining outstanding
R&D and marketing capabilities. In the U.S., Astellas markets
products in the areas of Anti-Infectives, Cardiology, Dermatology,
Neuroscience, Transplant, Oncology and Urology. For more
information about Ast
‘/>”/>
